Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program | Zendy

М. В. Шестакова | Zendy; Шестакова Марина Владимировна | Zendy

Open Access

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program

Author(s) -

М. В. Шестакова,

Шестакова Марина Владимировна

Publication year - 2010

Publication title -

diabetes mellitus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.155

H-Index - 12

eISSN - 2072-0378

pISSN - 2072-0351

DOI - 10.14341/2072-0351-5489

Subject(s) - sitagliptin , metformin , medicine , russian federation , type 2 diabetes mellitus , type 2 diabetes , sitagliptin phosphate , diabetes mellitus , endocrinology , insulin , business , economic policy

This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet and metformin monotherapy. They were transferred to the combined treatment with sitagliptin and metformin during 6 months. The mainend-points assessed in the study were hypoglycemic efficiency, frequency of side-effects, and satisfaction of patients and physicians with the treatment.The target HbA1c level

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research